Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Elaine Soliven, 24 Feb 2020
Administering intravenous propranolol hydrochloride does not reduce the duration of labour induction for nulliparous women who undergo vaginal delivery, according to a study presented at SMFM 2020.

Bermekimab holds therapeutic potential in hidradenitis suppurativa

03 Mar 2020

Interleukin (IL)-1α inhibition with bermekimab appears to be safe and effective in the treatment of moderate-to-severe hidradenitis suppurativa (HS), inducing clinical response without raising substantial safety concerns, according to the results of a phase II trial.

The trial included 42 HS patients, among whom 24 had previously failed anti-TNF therapy and 18 were anti-TNF naïve. All patients were subcutaneously administered bermekimab at 400 mg weekly (13 doses).

There were no treatment-related adverse events (AEs) recorded except for injection site reactions. A total of 58 nonserious AEs occurred, with most being grade 1 (59 percent) or 2 (36 percent). Two serious AEs were documented (grade 3 fall and grade 3 HS pain), none of which were related to bermekimab, and none led to treatment discontinuation.

In terms of efficacy, 61 percent of patients in the anti-TNF naïve group and 63 percent of those in the anti-TNF failure group achieved HS clinical response after 12 weeks of treatment. There were marked reductions in abscesses and inflammatory nodules seen in 60 percent (p<0.004) and 46 percent (p<0.001) of patients in the respective groups.

Furthermore, those experiencing pain showed clinically and statistically significant pain relief. The Visual Analogue Scale pain score decreased by 64 percent (p<0.001) in the anti-TNF naïve group and by 54 percent (p<0.001) in the anti-TNF failure group.

The present data point to IL-1α inhibition as an important clinical target for skin disease, with bermekimab potentially representing a new therapeutic option for managing moderate-to-severe HS, researchers said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Dec 2017
Supplementation with omega-3 fatty acids in combination with rosuvastatin may yield significant reductions in triglycerides and nonhigh-density lipoprotein (HDL) cholesterol as compared with rosuvastatin monotherapy, according to data from the ROMANTIC (rosuvastatin-omacor in residual hypertriglyceridemia) trial.
Elaine Soliven, 20 May 2020
Early treatment with a triple antiviral combination of lopinavir-ritonavir, ribavirin, and interferon beta-1b significantly shortens the duration of virus shedding and reduces symptoms in patients with mild-to-moderate COVID-19 compared with lopinavir-ritonavir only, according to a recent study.
Rachel Soon, 24 Apr 2019

With recent recalls of losartan-containing products contaminated by potentially carcinogenic nitrosamines, MIMS speaks to the Malaysian National Pharmaceutical Regulatory Agency (NPRA) for more details.

Elaine Soliven, 24 Feb 2020
Administering intravenous propranolol hydrochloride does not reduce the duration of labour induction for nulliparous women who undergo vaginal delivery, according to a study presented at SMFM 2020.